Company’s development platform and delivery system will be tested.
The PATH Malaria Vaccine Initiative (MVI) agreed to evaluate VGX Pharmaceuticals’ (VGX) SynCon™ DNA vaccine development platform. Vaccine development and malaria experts from the University of Pennsylvania School of Medicine will work with the company.
VGX will design and test DNA vaccine candidates using target antigens from Plasmodium species. Delivery will be done intradermally using its Cellectra® constant current electroporation device.
Cellectra is also being developed for the delivery of DNA vaccine and therapeutic candidates via intramuscular routes. Furthest along in VCX’ pipeline are Pennvax™-B as a preventive and therapeutic vaccine for HIV infection and VGX-3100 as a therapeutic vaccine for cervical cancer. Both are in Phase I testing.